ABBOTT LABORATORIES (ABT)
Sector: Health Care
2026 Annual Meeting Analysis
ABBOTT LABORATORIES · Meeting: April 24, 2026
Directors FOR
12
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of the 12 director nominees named in this proxy statement to hold office until the next Annual Meeting or until the next meeting of shareholders at which directors are elected
Dr. Ahuja joined the board in December 2025 and is exempt from the TSR trigger under the 24-month new-director exemption; she brings deep medical science and healthcare delivery expertise highly relevant to Abbott's business.
Director since 2022; Abbott's 3-year price return of +20.3% outperforms the IHI — iShares US Medical Devices ETF benchmark by +11.0 percentage points, well below the 65-point threshold required to trigger a vote against; she brings relevant finance and supply chain expertise.
Director since 2011; Abbott's strong 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, far below the 65-point underperformance threshold needed to trigger a no vote; she contributes strategy and governance expertise.
Chairman and CEO since 2021; Abbott's 3-year TSR of +20.3% outpaces the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well short of the 65-point threshold; no TSR trigger applies, and no overboarding or other governance concerns are present.
Director since 2021; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, far below the 65-point underperformance threshold; she brings strong financial planning and corporate finance expertise as an audit committee member.
Director since 2018; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point threshold; she serves on the audit and compensation committees and contributes manufacturing and operational expertise; she holds two outside public company board seats, which does not exceed the four-seat limit for non-executive directors.
Director since 2019; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point threshold; he holds two outside public company board seats (Parsons Corporation, GE Aerospace), within the permitted limit, and contributes risk management and cybersecurity expertise.
Lead Independent Director since 2011; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, far below the 65-point threshold; she serves on two outside public company boards (Accenture, Mondelēz), within the permitted limit, and is designated as the audit committee financial expert.
Director since 2023; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point threshold; as a sitting CEO he holds one outside public board seat (Abbott), within the two-seat limit; he brings deep financial and risk management expertise.
Director since 2021; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point threshold; he holds one outside public board seat (Waystar), well within limits, and contributes extensive manufacturing and global operations expertise.
Director since 2017; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, far below the 65-point threshold; he brings deep medical device industry expertise as former Chairman and CEO of St. Jude Medical.
Director since 2017; Abbott's 3-year TSR outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point threshold; he holds one outside public board seat (General Dynamics), within limits, and contributes broad operational and risk management expertise.
All 12 director nominees pass the TSR trigger test: Abbott's 3-year price return of +20.3% outperforms the IHI — iShares US Medical Devices ETF by +11.0 percentage points, far below the 65-point underperformance threshold required to trigger a no vote for strong-positive-TSR companies. No overboarding, attendance, independence, or familial relationship concerns were identified. The board is 92% independent with a well-disclosed skills matrix and robust refreshment record. Vote FOR all nominees.
Say on Pay
✓ FORCEO
Robert B. Ford
Total Comp
$23,173,052
Prior Support
91% (six-year average)%
Abbott's total compensation program is well-structured: approximately 86% of executive pay is variable and performance-based, with annual bonuses tied to a formula covering sales, EPS, return on assets, free cash flow, and strategic metrics, and long-term stock awards (split equally between stock options and performance-based restricted shares) tied to both company TSR versus peers and individual multi-year contribution scores. CEO Robert Ford's reported total compensation of approximately $23.2 million is consistent with the structure of a diversified large-cap healthcare company of Abbott's scale, and his long-term incentive award of $17.6 million was set at 110% of the peer-group guideline reflecting strong sustained TSR performance above the peer median on one-, three-, and five-year bases. Abbott's say-on-pay votes have averaged 91% support over the past six years, a clawback policy meeting Dodd-Frank requirements is in place, and no concerns around guaranteed bonuses, tax gross-ups, or excessive fixed pay were identified.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
Ernst & Young is a Big 4 firm fully appropriate for a company of Abbott's size and complexity. The proxy filing does not explicitly state EY's tenure in years or break out the audit fee table in a form that can be extracted from the provided text, so neither the tenure trigger nor the non-audit fee ratio trigger can be confirmed as firing; per policy, the tenure trigger requires confirmed data and defaults to FOR in its absence. No material financial restatements were disclosed. The board's FOR recommendation is supported.
Overall Assessment
Abbott's 2026 annual meeting presents a clean ballot with no contested proposals: all 12 director nominees pass the TSR performance screen (Abbott's 3-year return outpaces the IHI — iShares US Medical Devices ETF by +11.0 percentage points, well below the 65-point trigger), the executive compensation program is strongly performance-linked with 86% variable pay and consistent shareholder support averaging 91% over six years, and Ernst & Young's appointment raises no fee-ratio or adequacy concerns based on available data. The two equity plan proposals (Items 4 and 5) fall outside the current policy scope and are not evaluated.